Overview

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of IBI112 induction therapy in patients with moderate and severe active Ulcerative Colitis (UC) to achieve clinical remission.
Phase:
Phase 2
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.